SCHEMBL531913

SCHEMBL531913

CC1Oc2ccc(-c3cccc(C(=O)NCc4ccccc4)c3)cc2NC1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.59
KDR P35968 2/20 0.52
CFD P00746 1/20 0.52
EPHX2 P34913 1/20 0.50
NR1H4 Q96RI1 1/20 0.50
ERN1 O75460 2/20 0.49
SMYD3 Q9H7B4 2/20 0.47
JAK2 O60674 1/20 0.47
MAP4K4 O95819 1/20 0.47
CHEK2 O96017 1/20 0.47
PRKCG P05129 1/20 0.47
CDK1 P06493 1/20 0.47
FES P07332 1/20 0.47
RET P07949 1/20 0.47
ROS1 P08922 1/20 0.47
FER P16591 1/20 0.47
FLT1 P17948 1/20 0.47
AXL P30530 1/20 0.47
FLT4 P35916 1/20 0.47
FLT3 P36888 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL532077 0.88 KDR (0.55) PARP1KDRSMYD3ROCK1
SCHEMBL531713 0.84 KDR (0.58) PARP1KDRSMYD3
SCHEMBL532007 0.83 KDR (0.53) PARP1KDRSMYD3ALDH1A1GAA
SCHEMBL532744 0.80 KDR (0.52) PARP1KDRERN1SMYD3
SCHEMBL7001705 0.79 PARP1 (0.64) PARP1KDRSMYD3GAA
SCHEMBL10267424 0.76 PARP1 (0.88) PARP1SMYD3POLB
SCHEMBL5470019 0.75 PARP1 (0.67) PARP1KDRSMYD3HSD17B10ALDH1A1
SCHEMBL531829 0.75 PARP1 (0.64) PARP1SMYD3HSD17B10ALDH1A1GAA
SCHEMBL6310170 0.75 PARP1 (0.95) PARP1SMYD3HSD17B10POLB
SCHEMBL532477 0.75 PARP1 (1.00) PARP1SMYD3HSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
WO-2010111626-A2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 PARP1 1/4885KDR 1627/4885CFD 3018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.